Search

Your search keyword '"Di Bartolomeo M"' showing total 5 results
Start Over Author "Di Bartolomeo M" Journal british journal of cancer
5 results on '"Di Bartolomeo M"'

1. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

Author

Buzzoni, R., Biganzoli, L., Bajetta, E., Celio, L., Fornasiero, A., Mariani, L., Zilembo, N., Di Bartolomeo, M., Di Leo, A., and Arcangeli, G.

Subjects
Adult, Breast Neoplasms, Estrogens, Luteinizing Hormone, Middle Aged, Tamoxifen, Premenopause, Antineoplastic Combined Chemotherapy Protocols, Goserelin, Humans, Female, Testosterone, Follicle Stimulating Hormone, Research Article
Abstract

It has been suggested that tamoxifen may improve the efficacy of medical castration with luteinising hormone-releasing hormone analogues, but very few data have so far been published concerning the clinical and endocrinological activity of this therapeutic modality. In this phase II multicentre trial conducted by the Italian Trials in Medical Oncology group (ITMO), 64 premenopausal patients with hormone receptor-positive or unknown breast cancer were treated with monthly s.c. injections of goserelin 3.6 mg, in association with a tamoxifen daily dose of 20 mg, as first-line therapy for their advanced disease. All of the patients were evaluable for efficacy and there was an overall response rate of 41% (95% confidence interval 28-52%), with 7 of the 26 responders achieving complete remission. The median time to response was 4 months (range 2-17), and the median response duration was 13 months (range 6-37 +). Better responses were observed in soft tissues (51%); the response in visceral and bone metastases was respectively 19% and 37%. Serum concentrations of gonadotrophins and oestradiol were significantly decreased by the treatment, oestrogen levels being constantly suppressed to within the range observed in post-menopausal women. No significant change was detected in serum testosterone levels. In our experience, although it was not associated with any increased clinical efficacy, the concurrent use of goserelin and tamoxifen proved to be a feasible approach in the management of premenopausal advanced breast cancer.

Published
1995

2. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study

Author

Bajetta, E, primary, Di Bartolomeo, M, additional, Carnaghi, C, additional, Buzzoni, R, additional, Mariani, L, additional, Gebbia, V, additional, Comella, G, additional, Pinotti, G, additional, Ianniello, G, additional, Schieppati, G, additional, Bochicchio, AM, additional, and Maiorino, L, additional

Published
1998
Full Text
View/download PDF

4. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.

Author

Bajetta, E., Di Bartolomeo, M., Buzzoni, R., Mariani, L., Zilembo, N., Ferrario, E., Lo Vullo, S., Aitini, E., Isa, L., Barone, C., Jacobelli, S., Recaldin, E., Pinotti, G., and Iop, A.

Subjects
*URACIL, *COLON cancer, *FOLINIC acid, *METASTASIS, *CANCER, *ANTINEOPLASTIC agents, *CAMPTOTHECIN, *COLON tumors, *COMPARATIVE studies, *FLUOROURACIL, *HETEROCYCLIC compounds, *RESEARCH methodology, *MEDICAL cooperation, *ORGANOPLATINUM compounds, *RESEARCH, *EVALUATION research, *RANDOMIZED controlled trials, RECTUM tumors
Abstract

This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX). One hundred and forty-three patients with measurable, non-resectable metastatic colorectal cancer were randomised in a multicentre study to receive TEGAFIRI (UFT 250 mg m(-2) day days 1-14, LV 90 mg day days 1-14, irinotecan 240 mg m(-2) day 1; q21) or TEGAFOX (UFT 250 mg m(-2) day days 1-14, LV 90 mg day days 1-14, oxaliplatin 120 mg m(-2) day 1; q21). Among 143 randomised patients, 141 were analysed (68 received TEGAFIRI and 73 TEGAFOX). The main characteristics of the two arms were well balanced. The most common grade 3-4 treatment-related adverse events were neutropenia (13% of cases with TEGAFIRI; 1% in the TEGAFOX group). Diarrhoea was prevalent in the TEGAFIRI arm (16%) vs TEGAFOX (4%). Six complete remission (CR) and 19 partial remission (PR) were recorded in the TEGAFIRI arm (odds ratio (OR): 41.7; 95% confidence limit (CL), 29.1-55.1%), and six CR and 22 PR were recorded in the TEGAFOX group, (OR: 38.9; 95% CL, 27.6-51.1). At a median time follow-up of 17 months (intequartile (IQ) range 12-23), a median survival probability of 20 and 19 months was obtained in the TEGAFIRI and TEGAFOX groups, respectively. Median time to progression was 8 months for both groups. TEGAFIRI and TEGAFOX are both effective and tolerable first-line therapies in MCRC patients. The employment of UFT/LV given in doublet combination is interesting and the presented data appear comparable to equivalent infusion regimens described in the literature. The safety profile of the two combinations also allows an evaluation with other biological agents such as monoclonal antibodies. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

5. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.

Author

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, and Di Nicolantonio F

Subjects
Cell Line, Crizotinib, Disease Progression, Fatal Outcome, Gene Amplification, Humans, Indoles administration & dosage, Middle Aged, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins c-met antagonists & inhibitors, Pyrazoles administration & dosage, Pyridines administration & dosage, Rectal Neoplasms pathology, Sulfonamides administration & dosage, Vemurafenib, Antineoplastic Combined Chemotherapy Protocols therapeutic use, DNA, Neoplasm blood, Drug Resistance, Neoplasm genetics, Proto-Oncogene Proteins c-met genetics, Rectal Neoplasms drug therapy, Rectal Neoplasms genetics
Abstract

Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAF V600E and MET amplification. However after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug combination is unknown., Methods: We analysed plasma circulating tumour DNA obtained at progression by exome sequencing and digital PCR. MET gene and mRNA in situ hybridisation analyses in two bioptic specimens obtained at progression were used to confirm the plasma data., Results: We identified in plasma MET gene hyper-amplification as a potential mechanism underlying therapy resistance. Increased MET gene copy and transcript levels were detected in liver and lymph node metastatic biopsies. Finally, transduction of MET in BRAF mutant colorectal cancer cells conferred refractoriness to BRAF and MET inhibition., Conclusions: We identified in a rectal cancer patient MET gene hyper-amplification as mechanism of resistance to dual BRAF and MET inhibition.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results